Biocon's GLP-1 revenue will exceed $500 million by end of 2026

Biocon's generic GLP-1 portfolio is expected to ramp up significantly in 2026 due to regulatory approvals and market demand. The company's focus on high-margin injectables and oral formulations could drive revenue beyond earlier projections.

Implied probability (Yes)

68%